HOME > ARCHIVE

ARCHIVE

STATISTICS

March 20, 2006
SEMINAR

March 20, 2006
Major Products, Major Firms Hit Hard: NHI Price Revision

March 20, 2006
HUMAN RESOURCES

March 20, 2006
Proposed Policy on Return of Goods Approved by Ryukaikon

March 13, 2006
Korosho Wants to See All Original Brands Available at the Same Strengths

March 13, 2006
REGULATORY NEWS IN BRIEF

March 13, 2006
Hayashibara to Develop Alzheimer's Disease Vaccine

March 13, 2006
Explanatory Meeting on JapicCTI

March 13, 2006
＜JCROA Seminar＞Collaborative Int'l Trials Remain Risky: Dr Iwasaki of EFPIA

March 13, 2006
GENERICS NEWS IN BRIEF

March 13, 2006
R&D NEWS IN BRIEF

March 13, 2006
Eisai Aims at \1 Tril. Sales in FY2011

March 13, 2006
SELF-MEDICATION NEWS IN BRIEF

March 13, 2006
Mr Iwasaki to Implement Reform through Dialogues with Employees: Pfizer

March 13, 2006
OPINION

March 13, 2006
Takeda Promoting Basen OD Tables to Win Market Competition

March 13, 2006
JPA Holds 100th Assembly of House of Delegates

March 13, 2006
Norvasc Was Most-prescribed Drug in 2005: IMS Japan

March 13, 2006
MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

March 13, 2006

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…